CTL-Tumor Cell Interaction: The Generation of Molecular Probes of Monitoring the HLA-A*0201-HER-2/neu Peptide Complex

Abstract

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and ABSTRACT (Maximum 200 Words)The overall goal of this project is to probe the CTL -tumor cell interaction by generating scFv probes that are able to recognize the HLA-A*0201-HER-2/neu 3 69_ 377 peptide complex. In the 12 month period covered by this report, I have successfully generated HLA-A*0201-HER-2/neu 3 69_ 377 complexes, and have isolated two scFv fragment clones that recognize this complex. In addition, I have started to analyze the expression levels of antigen processing machinery (APM) components, HLA class I antigens and P2m in several breast carcinoma cell lines. This analysis takes advantage of the availability of a wide panel of mAb to these antigens that several investigators in our laboratory, including myself, have developed and characterized. Collectively, the results we have obtained strongly support our future analysis to correlate the expression levels of APM components, HLA class I antigens, 32m and HER-2/neu with the levels of HLA-A*0201-HER-2/neu 3 69_ 37 7 complexes on breast carcinoma cells and lesions. The information derived from these studies is expected to contribute to our knowledge of the variables that influence the levels of HLA class I antigen-TAA derived peptide complex expression on breast carcinoma cells. I have successfully initiated many of the project tasks outlined in the Statement of Work. In collaboration with other investigators from our laboratory, I participated in the development and characterization of a panel of monoclonal antibodies (mAb) that are specific for proteasome and immunoproteasome subunits. The availability of these mAb, along with panels of mAb that recognize other antigen processing machinery (APM) components as well as surface HLA class I antigen and 032-microglobulin (032m), have enabled me to analyze the expression of these antigens in several breast carcinoma cell lines. In addition, I have been able to generate and purify HLA-A*0201-HER-2/neu 369 . 377 peptide complexes. By panning a semi-synthetic phage display scFv library with these complexes, I have successfully isolated two scFv fragment clones that react specifically with this complex.An immediate future goal of this project will be to increase the avidity of the HLA-A*0201-HER-2/neu 369 . 377 peptide complex-specific scFv fragments by generating scFv tetramers. In addition, the expression levels of APM components, HLA class I antigen and 032m on other breast carcinoma cell lines and on frozen section...